Bioventus (BVS) Corporate presentation summary

Market leadership and growth prospects

• Holds leadership positions across pain treatments, surgical solutions, and restorative therapies, with a $6.4B addressable market and $568M in 2025 revenue.

• Focuses on differentiated energy and orthobiologic solutions for musculoskeletal conditions.

• Portfolio includes HA viscosupplements, PRP, PNS, ultrasonics, and bone graft substitutes.

Strategic actions and financial performance

• Advanced portfolio with new growth drivers and divested non-core assets.

• Achieved 7.5% organic revenue growth and 20.5% adjusted EBITDA margin in 2025, with future targets above 10% growth and ~25% margin.

• Delivered over $100M in operating cash flow and expanded EBITDA margins by ~700 bps.

Growth portfolio and investment priorities

• Core products (HA, BGS, fracture care) drive majority of sales and strong margins.

• Emerging platforms (PNS, PRP) and expansion areas (ultrasonics, international) targeted for accelerated growth.

• Investments prioritized for PNS sales force, international expansion, and R&D for PNS and ultrasonics.